Late last month, the U.S. Food and Drug Administration (FDA) approved a monkeypox vaccine that is known to “shed from the vaccination site” and cause heart inflammation in about 1 in every 175 persons.
ACAM2000, made by Emergent BioSolutions, was developed to prevent monkeypox disease in individuals determined to be at high risk for mpox infection. But according to the FDA’s own medication guide for the product, the risks of the vaccine appear to outweigh the benefits.
Read More